로딩 중…
지수 로딩 중…
HLB INC.
028300· KOSDAQ· Health Care· Health Care Equipment & Services
₩41,800+4.50%
2026-11-02
Financials
Valuation Metrics
HLB INC.'s Market Cap is ₩5.6T. At end of 2025 it was ₩6.8T. Ranked #90 of 2,405 in KR market (top 4%), #6 of 1,627 on KOSDAQ (top 0.4%), #1 of 94 in Health Care Equipment & Services (top 1%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 5.57T KRW | KR#90/2,405 Sec#1/94 |
| Revenue | 97.47B KRW | KR#1,430/2,405 Sec#38/94 |
| Net Income | -227.03B KRW | KR—/2,405 Sec—/94 |
| Total Assets | 907.98B KRW | KR#505/2,405 Sec#6/94 |
| Net Assets | 422.44B KRW | KR#576/2,405 Sec#8/94 |
| Employees | 168 | KR#1,224/2,405 Sec#40/94 |
| Value | ||
| P/B | 13.19x | KR#2,376/2,405 Sec#93/94 |
| P/S | 57.16x | KR#2,361/2,405 Sec#93/94 |
| FCF Yield | -1.97% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | -53.74% | KR#2,272/2,405 Sec#87/94 |
| ROA | -25.00% | KR#2,268/2,405 Sec#83/94 |
| Op. Margin | -100.66% | KR#2,285/2,405 Sec#83/94 |
| Revenue Growth | 28.97% | KR#399/2,405 Sec#21/94 |
| Financial Health | ||
| Debt Ratio | 114.94% | KR#1,666/2,405 Sec#82/94 |
| FCF | -109.53B KRW | KR#2,128/2,405 Sec#83/94 |
| Cash | 26.38B KRW | KR#1,084/2,405 Sec#28/94 |
| Current Ratio | 0.26x | KR#2,204/2,405 Sec#92/94 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,405 Sec—/94 |
| Performance | ||
| 1Y Return | -13.99% | KR#888/2,405 Sec#23/94 |
| 1M Return | 3.34% | KR#202/2,405 Sec#6/94 |
| From 52W High | -39.60% | KR#734/2,405 Sec#28/94 |
| 1Y MDD | -62.39% | KR#1,577/2,405 Sec#53/94 |
| Trading | ||
| Volume | 466,393 shares | KR#165/2,405 Sec#4/94 |
| Trading Value | 19.02B KRW | KR#123/2,405 Sec#3/94 |
| Foreign Own. | 17.75% | KR#261/2,405 Sec#6/94 |
| Per Share | ||
| EPS | -1,703 KRW | KR—/2,405 Sec—/94 |
| BPS | 3,170 KRW | KR#1,833/2,405 Sec#58/94 |
Company Info
동사는 1985년 설립돼 1996년 코스닥에 상장한 바이오 의약품 회사로, 2023년 선박사업부를 물적분할해 HLB이엔지를 설립함. 헬스케어사업부는 체외진단 의료기기, 의약외품, 의료소모품을 제조·판매하고, Elevar와 Immunomic Therapeutics는 항암제 및 면역치료제를 개발하고 있음. 동사는 첨단 바이오 연구소 설립, 리보세라닙 치료제 FDA 승인 추진 등 혁신신약 개발로 글로벌 성장하고 있음. HLB는 1985년에 설립되었으며 세종특별자치시 연동면에 본사를 두고 있습니다.